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Abstract Formal economic evaluation is playing an increasingly important role in health-care decision-making.This is
shownby the requirementto presenteconomicdata to support applications for public reimbursement fornewpharma-
ceuticals in Australia and the provinces of Canada, and by the appraisal process initiated by the National Institute for
Clinical Excellence in the U.K.This growing role of economic analysis applies asmuchto the field of asthma as anywhere.
This paper provides a detailed review of applied economic studies in asthma.The review is used to explore a range of
methodological issues in the field including the choice of perspective andmaximand, whether to use disease-specific or
genericmeasures of outcome andwhetherdecision-makers shouldreceive disaggregated cost and consequence data or
results that focus on an incremental cost-effectiveness ratio. It is concluded that, given the heterogeneity in decision-
makers’objectives and constraints, economic studies should be planned and executed in such away as tomaximize flex-
ibilityinhowresults are presented.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1474, available online athttp://www.sciencedirect.com
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Given the limited resources available for health care and
apolicydecision, inmostdevelopedcountries, toremove
theunregulatedmarket from the role of resource alloca-
tion, priorities need to be set in terms of which health-
care interventions and programmes should be funded.
Economic evaluation is a set of formal analytical techni-
ques to establish the e⁄ciency of alternative policy op-
tions and thereby assist with priority-setting. These
methods ful¢l an increasingly important role in health
service decision-making. In some countries this is im-
posed at a central level; for example, the need for formal
economic analysis to demonstrate thevalue formoneyof
new pharmaceutical products prior to public reimburse-
ment in Canada (1) and Australia (2). In the U.K. this
‘macro’regulatoryuse of economic evaluation is develop-
ing with the National Institute of Clinical Excellence (3).
Economic methods also have an important role in local
health service decision-making F for example, in the
development of hospital formularies.Accepted 4 November 2002
Correspondence shouldbe to: Prof.Mark J. Sculpher,Centre for Health
Economics,University of York,Heslington,York,YO10 5DD,UK.
Fax: 01904 433644; E-mail: mjs23@york.ac.ukThe importance of formal economic analysis in asthma
care is, inpart, a re£ection of theburdenof the disease in
terms of resource cost and health.Weiss et al. estimated
that the total cost of asthma in theUSwas $US6.2 billion
in 1990, with the cost to the health-care system contri-
buting 59% of this total (4). In the U.K., asthma was esti-
mated to cost society d843 million per year at 1988
prices, with total health-care costs for asthma running
at d344millionper annum (5).Whilst the costs of asthma
are related to severity of disease, and the most severe
asthmatics contribute a disproportionately high amount
to the total economic burden of disease, signi¢cant costs
are also incurred by the health-care system as a result of
poormanagement of milder patients (6).
Economic evaluation is also needed as a result of the
developmentof new forms ofmanagement, such as phar-
maceutical therapies, which often impose extra costs on
the health-care system but promise additional health
bene¢ts to patients. Despite the activity in economic
analysis in asthma, themethods thathavebeen employed
have been inconsistent (7), and there is little evidence
that their results have yet to impact on decision-making.
The variability in choice ofmethods is a re£ection of the
general uncertainty regarding appropriate analytical
tools in economic health care and, in particular, the
choice of costs and outcomes to incorporate.
ECONOMICEVALUATIONINASTHMA 509This paper describes themethods of economic evalua-
tion in asthma and critically assesses thepublished litera-
ture in this ¢eld. It focuses on the choice of costs and
outcomes in published studies and assesses whether
these endpoints are su⁄cient given the alternative ob-
jectives underlying the use of economic evaluation. An
important objective of the paper is to suggest ways in
which economic evaluation in asthma may improve deci-
sion-making.
PRINCIPLESOFECONOMIC
EVALUATIONINHEALTHCARE
De¢ning economic evaluation
Economic evaluation in health care is de¢ned as the com-
parison of alternative options in terms of their costs and
consequences (8). Alternative options refer to the range
of ways in which health-care resources can be deployed
to generate improved health in a given patient or
population group; for example, pharmaceutical and
surgical interventions, screening and health promotion
programmes.
Health-care costs refer to the value of physical re-
sources at the disposal of the health-care system; for ex-
ample, clinical and other sta¡, capital equipment and
buildings, and consumables such as drugs. In addition,
non-health service resources are frequently deployed as
part of the process of producing health-care, such as the
time of patients and their families.Consequences repre-
sent all the e¡ects of health careprogrammes other than
those on resources.Typically, thesewould include the im-
plications of options for individuals’ health, and these can
be positive or negative. However, consequences also in-
clude other e¡ects that individualsmay value, such as re-
assurance and information provision (9).
Establishing value formoney
Establishing thevalue formoneyof interventions involves
aggregation of the various costs and consequences of al-
ternative options within a comparative framework and
relating the di¡erential costbetweenoptions to theirdif-
ferential bene¢ts.There are two alternative approaches
to aggregation: cost^ e¡ectiveness analysis (CEA) and
cost^bene¢t analysis (CBA). Three types of CEA are
used: standard CEA, cost-utility analysis (CUA) and
cost-minimization analysis (CMA) (Table 1). The process
of aggregating costs is essentially identical in each form
of analysis and straightforwardgiven that all costs are ex-
pressed on a single monetary scale. The four forms of
analysis di¡er inhow they aggregate consequences. Stan-
dard CEA and CMA can only be used in speci¢c circum-
stances: CEA is used when only one measure of
consequence is considered important or di¡ers betweenthe options; CMA is used when evidence indicates that
there are no important di¡erences between options in
any non-resource consequence.
CUA and CBA are more £exible in that they o¡er
methods of combining various consequences of interven-
tions in a single bene¢t scale (Table 1). CUA usually fo-
cuses on the various health e¡ects of options (e.g. pain,
physical function, mental health) and synthesizes these,
with any implications for life expectancy, onto a single
scale, typically in the form of the quality-adjusted life-
year (QALY). CBA also values multi-dimensional conse-
quences onto a single scale but di¡ers from CUA in that
the scale is represented in monetary units. In practice,
CBA is rarely used in health care evaluations (10), in part
due to the di⁄culties of valuing health in monetary
terms.
Published economic evaluations in asthma
A literature search was undertaken using Medline, the
O⁄ce for Health Economics (OHE) Health Economic
Evaluations Database (HEED), the NHS Economic Eva-
luationDatabase and theCurrentContents on-linedata-
bases from 1985 to June 2002, with the purpose of
capturing all economic evaluations that have been pub-
lished to date in asthma. Studies which failed to conduct
a full economic evaluationwere excluded aswere studies
which failed to measure both costs and consequences of
treatment.Thus, studies that considered only costs with
no evidence of equivalent outcomes between competing
interventions were not included.
The results of this search are presented inTable 2. It is
clear thathealth economic terminologyhasbeen subject
to much misuse in the asthma literature. Some studies
claim to be cost-e¡ectiveness analyses, but in practice
only consider costs (11).Others evaluate e¡ectiveness in
terms of a reduction in the use of health-care resources,
which are also included in the cost component of the
analysis (12). Similarly, some studies claim to be cost-ben-
e¢t analyses but do not explicitly value consequences
and are essentially cost analyses (13,14). Only one pub-
lished study has used a true cost^bene¢t approach in
the economic evaluation of asthma (15). In this study, con-
sequences of therapy were valued using a willingness to
pay approach (16), and the authors were able to demon-
strate that budesonide was more cost^bene¢cial than
placebo in patients withmild asthma.
Table 2 shows a total of 33 studies published between
1985 and 2002 that met the inclusion criteria.Of these,
27 were standard CEAs, four took a disaggregated ap-
proach to costs and consequences, whilst there was
one example each of CMA and CBA. Despite some
methodological work in asthma (17^19) and its impor-
tance for some decision-makers, there were only two
examples of CUA. Given the preponderance of CEA,
TABLE 1. Methods for aggregating costs andbene¢ts in economic evaluation
Type of analysis Aggregation of bene¢ts Establishing value formoney
Cost-e¡ectiveness analysis (CEA)
Three variants
Standard CEA Bene¢ts expressed on a natural scale
that represents (a) the only important
consequence ofthe options or
(b) the onlyconsequence onwhich
the options di¡er e.g. symptom-free
dayin asthma
If one option is less costly andgenerates at
least asmuchbene¢t (or producesgreater
bene¢t and is nomore costly) than its
comparators, it is dominant and considered
cost-e¡ective.If amore costlyoption is also
more e¡ective, its incremental cost per
extra unitof bene¢t (ICER) is presented
(relative to the otheroptionsbeingevaluated)
and comparedwith other uses of health
service resourcesusually in the same
clinical area
Cost^utility analysis A fullrange of health e¡ects of options
are expressed on a single scale,
usually the QALY
Sameprocess as for standard CEA, butthe
ICER takes the formofthe incremental
cost per additional QALYwhich facilitates
comparison across programmes and specialties
Cost^minimization analysis Usedwhen evidence indicates thatthere
are no importantdi¡erencesbetween
the options in anynon-resource
consequence
The less or leastcostlyoption dominates its
comparator(s) and can be considered
more cost-e¡ective
Cost^bene¢t analysis The full range of health (and other
non-resource) consequences are valued
inmonetary terms and aggregated to
generate a single estimate of bene¢t
Costs andbene¢ts are both on a single
(monetary) scale, the net bene¢t
(bene¢tsminus costs) is presented.
Anegative net bene¢t is notgoodvalue
ormoney.Positive net bene¢ts are
comparedwith other uses of
health-care resources
ICER: incremental cost-e¡ectiveness ratio;QALY: quality-adjusted life-year.
510 RESPIRATORYMEDICINEthe remainder of this paper focuses on this form of ana-
lysis.
DECISIONRULES INCEA
Within the framework of CEA, identifying a preferred
option from among those being compared (‘decision
rules’) involves relating di¡erences in costs to di¡erences
inbene¢ts. In the case of an optionbeing dominant (cost-
ing less and generating at least as much bene¢t, or pro-
ducing greater bene¢t and being no more costly than its
comparators), it is unequivocally cost-e¡ective. How-
ever, if an option generates additional bene¢ts it can still
be considered cost-e¡ective even if it also increases
costs. In such a situation, the option’s incremental cost
per additional unit of bene¢t is calculated and compared
with other uses of health serviceresources.For example,
if an incremental cost-e¡ectiveness ratio (ICER) was cal-
culated for a new asthma drug relative to standard prac-
tice, the only way inwhich an assessment could bemade
regarding whether the additional cost of the new drug isworth incurring to reap its extra bene¢t is to compare
its ICER with those of asthma treatment options not
considered in the evaluation (e.g. implement a new asth-
ma treatment or fund an asthma self-management pro-
gramme).This sort of comparison can establishwhether,
in a resource-limited system, the independent options
with a higher ICER should be scaled-down or stopped
to fund the new asthma drug, with the health-care sys-
tem generating a net gain in bene¢ts. Recently, it has
been argued that the ICER should be replaced due to its
statistical intractability and replaced by the concept of
netbene¢t (20).However, themain principles of CEAre-
main largely unchanged.
MEASURINGCOSTSAND
CONSEQUENCES INASTHMA
Although the principles of CEA are clear, there are no
¢rm implications regarding the most appropriate mea-
sures of costs and consequences to incorporate into an
analysis. In the contextof economic evaluation in asthma,
TABLE 2. Summaryof publishedhealth economic studies in asthma1985^2002
Studydescription Design Measures of e¡ectiveness Costsmeasured Keymessages
(i) Treatment comparisons
Andersson et al. (34).Cost-e¡ectiveness
of adding FORM to BUD
inmoderate asthma
CEAusingdata from
a12-month RCT plus survey
of experts
Symptom-free days Direct and indirect
(productivity) costs for
three European countries
Adding FORM to low -doses
of BUDis cost-e¡ective
Barnes et al. (35).Economic
meta-analysis of FP vs.BUD
CEAusingameta-analysis
of RCTs
Improvement in PEF, symptom-
free days, episode-free days
Direct heath-care costs Athalf the dose,FP more
cost-e¡ective than BUD
Berggren and Ekstrom (36).
Cost-e¡ectiveness
of FORMcompared to terbutaline
inmoderate-to-severe asthma
CEA alongside12-week RCT Severe exacerbations Drugcosts, physicianvisits
andproductivitycosts
FORMismore e¡ective
andgenerates cost savings
Bisgaard et al (37).Cost-e¡ectiveness
of FP via MDI vs.
standard therapywith bronchodilators
in pre-school children
CEA alongside12-week RCT Exacerbations,
symptom-free days
Direct health service costs FP via MDIismore cost-e¡ective
than standard therapywith
bronchodilators
Booth et al. (38).Acomparative
CEAof ICS in asthma
CEAusingdata froman
8-week RCT
Improvement inmorning PEF All asthma-related
medication costs
FP more cost-e¡ective than BUD
Booth et al. (39). Acomparative
CEAof FP vs.SCGinpaediatric asthma
CEAusingdata froman
8-week RCT
Multiplemeasures
of e¡ectiveness
addressing symptoms,
sleep disturbance and PEF
All asthma-related
medication costs
FP more cost-e¡ective than SCG
Van den Boom et al. (29).
Cost-e¡ectiveness of early
treatmentwith FP in obstructive
airwaydisease
CUA and CEAusingdata from
a12-month RCT
QALYs,FEV1 Direct and indirect
(productivity) costs
Incremental cost per additional
QALYof £uticasone US$13 016
forearly treatment, and
US$33 921fordetection
and treatment
Campbell et al. (40).Comparison
ofthe cost-e¡ectiveness of BUD
400 mgand 800 mg in
mild-moderate asthma
CEAusing-data froma
12-week RCT
PEFand symptoms Notclear BUD 400 mgmore cost-e¡ective
than BUD 800 mg
Connett et al. (41).Cost-e¡ectiveness
of BUDin children aged1^3 years
CEAusingdata froma
6-month RCT
Symptom-free days Direct and indirectcosts BUDreduced overallhealth-care
costs, productivity loss, and
increased symptom-free days
Everden et al. (42).Cost-e¡ectiveness
of eformoterol Turbohaler vs. SALM
in childrenwith symptomatic asthma
CEAusingdata onproportion
of patients in a12-week RCT
Symptom-free days Direct health-care costs Eformoterolwas found to be
more e¡ective and less costly
Lundbacket al. (43).CEAofthree
studies comparing SFC
(50/100, 50/250 and 50/500 mg)
with an equivalentdose of FP alone
CEAusingdata fromthree
12-week RCTs
Improvement in PEF,
ymptom-free days,
episode-free days
Direct health-care costs SFC associatedwith improved
outcomes at a small increase
in costs comparedwith FP alone
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Lundbacket al. (44).Cost-e¡ectiveness
of SFCcompared to
BUDinmoderate-to-severe asthma
CEAusingdata froma
24-week RCT
Improvement in PEF,
Symptom-free days,
episode-free days
Direct health-care costs
(Swedish Krona)
Incremental cost per successfully treated
week (based on improvement in PEF)
SEK 31.6; incremental cost per episode-
free day SEK 7.7; incremental cost per
symptom-free day SEK 9.2
Menendezet al. (45).Cost-e¡ectiveness
of FP vs. za¢rlukast
in patientswith persistent asthma
CEAusingdata froma
12-week RCT
Symptom-free days,FEV1 Direct health service costs Treatmentwith FP wasmore
cost-e¡ective than za¢rlukast,
beingless costly andmore e¡ective
O’Byrne et al. (15).E⁄cacy and CBAof
BUD 400 and 800 mg inmild asthma
CBA (willingness to pay)
over 4 months
Bene¢ts valued in
monetaryunits
Directcosts BUD 400 and 800 mgare
cost-bene¢cialvs. placebo
Paltiel et al. (28).Cost-e¡ectiveness of
inhaled corticosteroids plus short-acting
B-agonists compared to short-acting
B-agonists alone
CUA and CEAbased on
decisionmodel and
synthesis of published data
QALYs, symptom-free days Direct health-care costs The incremental cost per additional
QALYof inhaled corticosteroids is
US$ 13500.The results are sensitive to
assumed e⁄cacy and side
e¡ectswith inhaled corticosteroids
Perera (46).Cost-e¡ectiveness of ICS
in children in developingcountries
CEA.Before and after studyover
4 years of BDPand BUD
Parental satisfaction Directmedical, non-medical
and indirectcosts
Implementation of ICStherapyreduced
overall costs and improvedparental
satisfactionratings
Price and Appleby (47).Primarycare
auditof outcomes and cost-e¡ectiveness
of FP inprimarycare
Non-randomized‘before
and after’cost and outcomes
analysis in clinicalpractice
PEF All directmedical costs Switching symptomatic asthma patients
to FP improved outcomes for a similar
overall cost
Rutten-van Molken et al. (48).
Cost-e¡ectiveness comparison
of SALMand FORM
CEAusingdata from
6-month RCT
Episode-free days and
improvement in
disease-speci¢c QoL
Comprehensive collection
of direct, direct
non-medical and indirectcosts
No cost-e¡ectiveness di¡erence
betweenthe treatments
Rutten-van Molken et al. (49).
Cost-e¡ectiveness of ICS and
bronchodilators in asthma and COPD
CEAusingdata from
a randomized 3-year trial
Symptom-free days,FEV1 Direct and indirectcosts ICSplus a bronchodilator is
cost-e¡ective vs a bronchodilator alone
Rutten-van Molken et al. (50).
Cost-e¡ectiveness of ICS and
bronchodilators vsbronchodilators
alone in asthma
CEAusingdata froma
randomized 2.5-year trial
Symptom-free days,FEV1 Directcosts Incremental cost per symptom-free
daywith ICS of US$ 5
Sculpher and Buxton (51).
Cost-e¡ectiveness of FORM
vs. salbutamolin asthma
CEAusingdata froma
12-week trial
Episode-free day Drugcosts Incremental cost per episode-free
dayof formoterol Can $ 5.67^7.29
Stanford et al. (52).Cost-e¡ectiveness
of FPcompared to inhaled
triamcinolone acetonide
CEAusingdata fromtwo
24-week RCTs
Symptom-free days,FEV1 Directcosts Incremental cost per symptom-free
day for FPUS$1.70
TABLE 2. (Continued)
Studydescription Design Measures of e¡ectiveness Costsmeasured Keymessages
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Steinmetzet al. (53).Cost-e¡ectiveness
of FP and BUDinmoderate asthma
CEAusingdata from
6-week RCT
Symptom-free days,
improvement in PEF, overall
treatmente¡ectiveness
All directmedical costs FPcheaper andmore e¡ective
than BUD
Stempel et al. (54).Comparative
cost-e¡ectiveness of FP and BUD
Meta-analysis of RCTs Symptom-free and
episode-free days
Directcosts to the
health-care payer
FP more e¡ective and less costly
than BUD
Venables et al. (55).Cost-e¡ectiveness
of BUDand FP in adult asthma
CEAusingdata from
8-weekopen-label RCT
Symptom-free days,
improvement in PEF
Drugcosts BUDmore cost-e¡ective than FP
Williams and Richards (56).
Economic analysis of FP and
BUDinpaediatric asthma
CEAusingdata from 4-week
clinical trial
Improvement in PEF Directmedication costs FP more cost-e¡ective than BUD
(ii) Device comparisons
Liljas et al. (57).Cost-e¡fectiveness
of DPI vs.MDI
CEAusingdata froma
1-year RCT
Asthma exacerbations
(e¡ectivelymeasuredby PEF)
Direct and indirectcosts Betteroutcomes and lower
costswiththe DPI
Turner et al. (58).Economic evaluation of
nebulizer vs.MDIin secondarycare
CMAfroma prospective
6-week audit
None (equivalentoutcomes) Direct secondarycare costs Administration of bronchodilators
via MDIis cheaper
(iii) Educational orguideline evaluations
Bolton et al. (59).Costs and e¡ectiveness
of an asthma self-managementplan
Analysis of costs and
consequences over a
12-monthperiod
Activity-limited days Direct health-care costs Decreasedutilization of health-care
resources in studygroup
Gallefoss and Bakke (60).
Cost-e¡ectiveness of
self-management in asthma
CEAusingdata froma
12-month RCT
FEV1,St Georges
Respiratory Questionnaire
Direct health-care costs, direct
costs to patients, productivity
costs (Norwegian Krone)
Includingproductivitycosts,
self-managementreduces costs
and improves outcomes; with direct
costs, the incremental cost per unit
of e¡ect is NOK 9.4^301
McFadden et al. (61).Evaluation of a
protocol for themanagementof
acute exacerbations inhospital
emergencyrooms
Costs and outcomes
evaluation over1year
Time to resolution of symptoms Direct hospital costs,
direct non-medical costs
Adherence to the treatmentprotocol
reduced costs to patient
andhospital, and improved time
to resolution of symptoms
Sondergaard et al. (62).Economics
of an asthma educationprogramme
Prospective cost^consequence
analysis
Avoidance of productivity loss,
QoL andhealth status
Directcosts (indirectcosts
avoidedwere used as
an e¡ectivenessmeasure)
Improvedhealth status and QoL.
Some costswere o¡-set.
Fewcostdi¡erences
Windsor et al. (63).Cost-e¡ectiveness of
a health educationprogramme
Prospective CEA Adherence score Sta¡ time costs in implementing
the programme
Costswere increased, and there
were improvements in adherence scores
BUD: budesonide;CBA: cost^bene¢t analysis;
CEA: cost^e¡ectiveness analysis;CMA: cost^minimization analysis;
CUA: cost^utility analysis;DP: drypowder inhaler;FEV1: forced
expiratory volume in1s;FORM: formoterol;FP: £uticasone propionate;
ICS: inhaled corticosteroid;MDI: metered dose inhaler;
PEF: peakexpiratory £ow;QALY: quality-adjusted life-years;
QoL: qualityof life;RCT: randomized controlled trial; SALM: salmeterol; SCG: sodiumcromoglycate; SFC: salmeterol/£uticasone propionate combinationtherapy.
EC
O
N
O
M
IC
EVA
LU
ATIO
N
IN
A
STH
M
A
513
514 RESPIRATORYMEDICINEthe variety of costs that have been considered in studies
is shown inTable 2. A range of perspectives have been
taken in the literature and include studieswhich consider
only asthma drug costs through to adoption of a full so-
cietal perspective by, for example, including productivity
costs.By far, themost common costs included in asthma
economic evaluations are direct health-care costs. Re-
gardless of the types of costs included, one common fail-
ing illustrated in the literature is that the perspective
taken for the analysis is rarely explicitly stated, even
when the types of costs included are clearly presented.
As well as a wide range of costs included in these stu-
dies, there has been an equally large variation in mea-
sures of consequence within asthma cost-e¡ectivenessTABLE 3. Summaryof endpoints used in economic evaluations i
Consequence
QALYs Based on directelici
based on standardg
Based on directelici
based ontime trade
othermethodsused
Improvement in PEF Z5%Weekly impro
with baseline predic
Improvement in PEF
Attainmentof desire
Dayswith PEFo80
Improvement in FEV1 10% Improvement in
12% Improvement fr
Change frombaselin
100mlgainrelative t
Symptom-free day Notde¢ned inpape
Total symptom score
daytime or 24-h sym
Total symptom score
No daytime sympto
Nonight-time symp
Time to resolution o
Episode-free day As de¢nedby Sculp
of asthma attack,
need for rescuemed
Monetary values Bene¢ts value inmo
to paymethodology
Patient satisfaction Mean satisfaction sc
Health-related qualityof life Achievinga clinically
St George’s Respirat
Improvement in asth
andpsychosomatic d
Activitylimitation/impacton activities School absenteeism
Activity-limited day
Exacerbations Need fororal cortic
Change inmedicatio
Treatment adherence score Percentage improve
aLevel of desired improvementconstitutinga‘success’was varia
FEV1: forced expiratory £owin1s;PEF: peakexpiratory £ow;QAanalyses (Table 3). Even where there is some agreement
across studies about the desired outcome of asthma
management, there is still a considerable degree of het-
erogeneity in how bene¢ts are expressed.
PERSPECTIVEANDMAXIMAND
Asmentionedabove, any assessmentofpublished studies
with respect to their choices regarding costs and conse-
quences needs to be clear about the appropriateness of a
study’s perspective (i.e. whose costs and bene¢ts arewe
interested in?) and its maximand (i.e. what bene¢ts are
we trying to maximize from limited resources when wen asthma
Variation References
tation of utilities frompatients
amble exercise
(29)
tation of utilities frompatients
-o¡ exercise;
in sensitivity analysis
(28)
vement inmorning PEFcompared
tedvalue
(35, 38,44)
frombaseline to end oftreatmenta (35,40,47, 53, 55, 56)
dpredicted PEFa (38,40)
% predicted (57)
predictedvalue frombaseline (49, 50,60)
ombaseline (45)
e (60)
o comparator (29)
r (40, 52)
of zero, althoughunclear if only
ptoms considered
(41,44,49, 50, 53, 54)
of zero over 24-h period (35,42, 55)
ms (28, 34, 37, 39,44)
toms (28, 37, 39,44,45)
f acute symptoms (61)
her and Buxton (51): absence
ication or sleep disturbance
(35,44,45,48,49, 54)
netary termsusingwillingness (15)
ore (46)
important improvement in
ory Questionnaire score
(48,60)
ma qualityof life questionnaire
iscomfort scale
(62)
(50)
s (59)
osteroids,PEF (36)
n, medical contact (37)
ment in adherence score (63)
ble between studies.
LYs: quality-adjusted life-years.
ECONOMICEVALUATIONINASTHMA 515undertake an economic evaluation?). In essence, these
are normative questions to which there is no correct
technical answer. There appear to be strong arguments
in favour of the health-care system seeking to maximize
some measure of population health; however, individual
decision-makersmayhave quite di¡erent ideas about the
most appropriate objective of resource allocation.
The choice of perspective in an analysis is also one
over which the various stakeholders in an evaluation
(analysts, patients, potential patients, clinicians, man-
agers) may have di¡erent views. There are strong argu-
ments in favour of considering the costs and
consequences of health care for all groups and individuals
(societal perspective) (21,22). Perhaps the strongest of
these arguments is that a societal perspective avoids
the risk that an option is deemed cost-e¡ective despite
a sub-group of the population or an organization experi-
encing signi¢cant negative consequences or additional
costs. For example, an education programme for asth-
matics may appear cost-e¡ective when only health ser-
vice costs are considered, but perhaps only because the
costs to patients (in terms of, for example, the time costs
of attending a education sessions) are ignored.However,
as with the choice of maximand, the individual decision-
maker may have a very narrow perspective. For exam-
ple, on the cost side, they may only be interested in the
impact of a new drug on the pharmacy budget.
Measuring consequences
Consequence measures in asthma
Table 3 shows that there is consistency in economic stu-
dies in asthma regarding the perspective they have em-
ployed: the individual with asthma is always the focus;
however, the table shows considerable variation in the
measures used including symptoms, exacerbations and
more formal health-related quality of life (QoL) mea-
sures.Table 3 identi¢es11di¡erentgroups of consequence
measures used in economic evaluation is asthma and,
even within these groups, there remains variation in the
speci¢c measures used. For example, although the ma-
jority of cost-e¡ectiveness studies chose to focus on
symptoms as their main measure of consequence, the
process of weighting and aggregation di¡ered markedly
between studies. Variants included symptom-free days
(with the actual de¢nition of a day unclear), symptom-
free 24-h periods and time to successful control.
The variability in consequence measure probably par-
tiallyre£ects the fact that the objectives of asthma inter-
ventions di¡er or have multiple objectives. For example,
bronchodilators have a mode of action that is more fo-
cused on short-term alleviation of symptoms and im-
provement in lung function, so it would seem
appropriate for endpointsmeasuring these facets to pre-
dominate in evaluations of these interventions. On theother hand, measures such as reduction in exacerba-
tions, improvement in health-related QoL and longer
term improvements in lung function and symptoms tend
to bemore important for prophylactic therapies such as
inhaled corticosteroids.
Asthma-speci¢cmeasures ofconsequence
The lack of consistency in consequencemeasures used in
studies has important implications for the usefulness of
economic data to decision-makers. As described above,
when a new therapy is more costly but also more bene-
¢cial than its comparator, an incremental cost per addi-
tional unit of bene¢t is calculated to provide a decision-
maker with an indication of how much more patients
are getting for the additional cost involved. To help in
the decision-making process, the ICER should be com-
pared with the same ratio calculated in other (i.e. inde-
pendent) evaluations.
For decision-makers to be able to make full use of the
data generated by such studies, there needs to be agree-
menton the appropriateperspective andmaximand, and
each study has to employ a common measure of conse-
quence that relates clearly to the maximand. If it is as-
sumed, for example, that the objective of caring for all
asthma patients is to maximize, from the limited re-
sources available in that area, the proportion of patients’
liveswithout symptoms, and if it is also agreed that the a
symptom-free day (SFD) could be de¢ned and used in all
CEA in asthma, then each study would compare its alter-
native treatments in terms of their costs and rates of
SFD. A dominant treatment (e.g. onewhich is less costly
than its comparator(s) and generates at least as many
SFDs) would clearly be cost-e¡ective andworth funding.
If the more costly therapy also achieved more SFDs, its
ICERwouldbe calculated (the incremental cost per addi-
tional SFD). If a number of studies in asthma had already
reported similar ratios, itwouldbepossible for decision-
makers to compare ICERs and assess whether resources
should be re-allocated in the area.
There are limitations to this focus on an asthma-speci-
¢c maximand and measure of consequence. The ¢rst is
the relevance of a single measure of consequence to all
patients with asthma. As noted above, di¡erent types
of therapy for di¡erent sub-groups of asthmatics are
likely to have a variety of clinical objectives. It may be
the case, for example, that minimizing symptoms and
the use of an SFD as the measure of consequence is not
appropriate for all sub-groups of asthmatics. Further-
more, an SFDmaybe interpreteddi¡erentlybetween in-
dividuals: for example, a severe asthmatic may de¢ne a
SFD in quite a di¡erentway to a mild asthmatic. In other
words, it may be very di⁄cult to identify a single maxi-
mand and common measure of consequence in CEA in
asthma.
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A second limitation of an asthma-speci¢c maximand is
that there may be good reason to fund more costly but
more bene¢cial therapies for asthma by re-allocating
budgets from outside of that particular clinical area. This
cross-programme resource allocation ismore clearly re-
lated to a broader maximand than symptoms in asthma.
If the cost-e¡ectiveness of new asthma treatments is to
be comparedwith that of interventions in a range of dif-
ferent specialties and disease areas, it is necessary to
agree on a broadmaximand, such as health in general.
With such a maximand, a new drug for asthma (which
is more costly and more bene¢cial than standard ther-
apy)wouldbe consideredcost-e¡ective if its incremental
cost per extra unit of health gain compared favourably
with health-care interventions inside or outside asthma.
In order to facilitate cross-programme resource alloca-
tion of this sort using a maximand of overall health, it is
necessary to incorporate generic measures of health
gain into CEA.The use of the QALYas a measure of con-
sequence, as described earlier and inTable 1, represents
the branch of CEA which focuses on supporting the
broader maximand of health. The process of estimating
QALYs in a given study is not a subject for detailed
consideration here and is covered elsewhere (8, 23, 24).
In brief, a popular approach to measuring QALYs
involves measuring patients’ health-related quality of
life (HRQoL) (within a trial or observational study)
using a generic measure that describes health in terms
that are not associated with a speci¢c disease or inter-
vention. It would then be necessary to score this instru-
ment in such a way that a single index (often called a
value or utility) is derived to re£ect a patient’s HRQoL
at any point in time running from 0 (equivalent to death)
to 1 (equivalent to good health).This scoring process in-
volves weighting the relative importance of di¡erent di-
mensions of HRQoL, and of di¡erent items within each
dimension, using utilities or preference scores,.This is in-
herently subjective and will re£ect the di¡erent prefer-
ences of individuals.
A number of generic ‘utility instruments’ now exist in
health care including the EuroQol (EQ) 5D (25), Health
Utilities Index (HUI) III (26), and Quality of Wellbeing
(QWB) Scale (24). Each of these instruments uses the
preferences of the general public to deriveutilityweights
for di¡erent domains and items in the HRQoL scale,
based on the view that, as the ultimate payers for health
care, it is societal views that should count in this respect
(21). An alternativeway tomeasureQALYs is to elicit uti-
lities directly frompatients relating to their own state of
health at a given time point. In a recent authoritative re-
view of good methodology in economic evaluation (21),
the use of societal utilities was preferred, and this has
beenmirrored inNICE’s technical guidance on economic
evaluation (27).AsTable 2 shows, there are two examples of theuse of
QALYs as a measure of consequence in economic evalua-
tions in asthma (28,29). In both cases, utilities were eli-
cited directly from patients, although Paltiel et al. (28)
also used the HUI as a sensitivity analysis. The limited
use of CUA in asthma is, in part, likely to be due to the
fact that QALY-based measures of consequence are in-
evitably less sensitive to clinical change than asthma-spe-
ci¢c measures. Generic classi¢cations of HRQoL are by
their nature not as focused on the speci¢c impact of a
disease or its treatments from the patient’s perspective
as a disease-speci¢c measure. For this reason, most stu-
dies have focused on asthma-speci¢cmeasures of conse-
quence in the hope of re£ecting clinically important
changes, despite the fact that this is of limited value for
cross-programme resource allocation.
A second reason why the use of QALYs has been rare
in asthma studies is the lack of consensus, on the part of
decision-makers, that health is the appropriate maxi-
mand and that the QALY is the relevant measure of
health in applied studies. Decisions need to be taken at
the ‘top of the service’ regarding resource allocation be-
tween specialties and programmes, and here a health
maximand, with QALYs as the best currently available
expression of that in evaluative studies, would seem ap-
propriate.This explains NICE’s preference for the QALY
(27). However, decisions on di¡erent types of resource
allocation need to be made lower down in the system,
andQALYsmaybe less relevant here.For example, there
is evidence that currently general practitioners do not
value the QALYas an ideal maximand in health-care de-
cision-making (30).
A third reason for the limited use of QALYs in asthma
may be the limited opportunities to evaluate QALY end-
pointswithin the frameworkof traditional drug develop-
ment. The majority of published economic analyses to
date havebeen conducted as part of clinical trials, whose
primary aim is regulatory approval or demonstration of
superior clinical e⁄cacy. From Table 2, it is clear that
many of these trials are of relatively short duration and
this, coupledwith theperceived lackof sensitivity of gen-
ericQALYs,mayhaveresulted in the limiteduse ofQALYs
in applied studies in asthma. If there is to be an increase
in theuse of thismeasure of bene¢t, itwill require great-
er investment in longer term, properly powered studies
that have economic evaluation as a primary aim.
Given the heterogeneity in the type of decisions that
need tobe taken inhealth care systems, there appears to
be a strong argument for economic studies in asthma to
take a pragmatic approach and o¡er a range of conse-
quence measures and, where appropriate, generate
ICERs using each of these. In other words, for cross-pro-
gramme resource allocation, the presentation of cost-ef-
fectiveness usingQALYs is desirable and ideally should be
factored into studies. However, this should be underta-
ken in parallel with asthma-speci¢c measures of conse-
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making within specialties and programmes.
Furthermore, if decision-makers are unwilling to be
explicit about a maximand for CEA, then it is important
for one of the outputs of studies to be a disaggregated
description of costs and all consequences.Often referred
to as cost-consequences analysis (8), this form of evalua-
tion essentially presents a balance sheet of the costs and
consequences of the two or more interventions under
comparison.
Measuring costs
Compared to the issues associated with the measure-
ment of consequences in economic evaluation, costmea-
surement is less contentious. However, some important
methodological uncertainties exist includinghow toesti-
mate accurate unit costs and the appropriate vehicle for
resource allocation measurement. These are discussed
fully elsewhere (8,21). Some methodological issues in
costing are particularly relevant to the economic apprai-
sal of asthma interventions. These include the choice of
perspective, valuation of time costs and the appropriate
time horizon.
Cost perspective
As noted above, there are strong reasons to take a soci-
etal perspective on costs.Of those economic studies in
asthma (Table2),12 studies included costs of lost produc-
tivity and could be argued to have adopted a broad soci-
etal perspective. One reason why some studies took a
narrower perspective than societal is probably the per-
ception that all or a sub-group of health-care decision-
makers are not interested in costs other than those fall-
ing on the health-care system. As with consequences, it
is likely that decision-makers at the various levels within
the system have di¡erent attitudes to the appropriate
cost perspective.
Given the variety of cost implications that are likely to
be of interest to decision-makers and the importance of
checking that a health-care intervention is not deemed
cost-e¡ective because not all its resource cost implica-
tionshavebeen included, a varietyof perspectives should
be adopted in economic studies in asthma.There is again
a strong case to present decision-makers with disaggre-
gated information on the resource implications of inter-
ventions and the cost of those resources within a cost^
consequences analysis.This allows decision-makers to in-
clude those costs they think appropriate inreaching ade-
cision.However, it is also important for data on all costs
to be made public and for the decisions that are ulti-
mately taken to be assessed against a societal perspec-
tive on costs.Valuing time costs
If, as argued above, a societal perspective should be part
of economic studies in asthma, an importantnon-health-
care cost is the value of the time of patients and carers
that is a¡ected by asthma and interventions to treat it.
Four time costs are relevant here: patients’ healthy time
that is lostdue to themorbidity andmortality associated
with asthma; the time patients put into the process of
receiving health care (e.g. visiting a clinic); and the time
carers put into caring for friends and relativeswith asth-
ma.
In principle, measuring these time inputs can be un-
dertaken in clinical trials and observational studies. It is
their valuationwhich raises di⁄cultmethodological pro-
blems.These issues have been discussed fully elsewhere
(21, 31). The key ones relating to economic evaluation in
asthmawould be:
K Whether time away fromusual activities as a result of
asthma shouldbevaluedinmonetary terms or aspart
of a QALY.
K Whether time away from school in paediatric asthma
should be valued in monetary terms and, if so, what
basis of valuation should be employed.
K How should carers’ time be valued: on the basis of a
shadow wage (i.e. the wage rate of someone who
would be formally employed caring for the sick),
average wage rates or the carer’s actual loss of
income.
Appropriatemethodology in this area is currently un-
clear and considerable research is required. In an applied
study in asthma, therefore, it would be appropriate to
use asmany valuation techniques as possible and to com-
pare their implications for the conclusions of a study.
Appropriate time horizon
The choice of time horizon is important in any study. In a
CEA, appropriateness should be judged according to the
time-point atwhich the options under consideration can
be expectednot to di¡er in terms of their costs and con-
sequences. Inevitably, there will be marked uncertainty
about this time-point, especially in the context of a
chronic disease such as asthma, where symptoms and
treatment may continue for many years.The problem is
accentuated in asthma by the short-term duration of
many of the clinical trials that provide the data for CEA.
As shown in Table2, the duration of trial-based studies
ranges from just 4 weeks to 4 years.Unless it can be as-
sumed that, after these points, di¡erential costs and
bene¢ts do not alter, shorter time horizons are likely to
be inappropriate, although theminimum acceptable time
frame for economic analysis in asthma is somewhat un-
clear.
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will have to include alternative or complementarymeth-
ods to short-term regulatory trials. These will include
long-term pragmatic trials, decision modelling to extra-
polate trial results over a longer time horizon and the
use of large longitudinal databases to generate long-term
resource use and consequence data to populate models.
Longer termpragmatic trials probably o¡er thebest op-
portunity of measuring QALY bene¢ts of asthma treat-
ments as there is likely to be a favourable time horizon
and themorenaturalistic settingmayreduce‘noise’ asso-
ciatedwith trial e¡ects.
CONCLUSIONS
National guidelines for economic evaluation in Canada
andAustralia are spreading across Europewith initiatives
established or in development in countries such as The
Netherlands, Ireland and the U.K. Following increasing
nationalrequirements, economic evidence is alsobecom-
ingkeydata for health-careproviders such asHMOs (32).
It is clear that the importance of formal economic ana-
lyses will only increase.
Economic evaluations of health-care technologies
should ideally facilitate better health-care decision-mak-
ing by explicitly identifying, measuring and valuing the
costs, consequences and trade-o¡s between competing
interventions. However, to enable competing interven-
tions to be compared and evaluated, there is a need for
a level of comparability across methodologies which is
currently lacking in the asthma literature.This is particu-
larly evident in the choice of consequences reported.
Even when similar measures of e¡ectiveness are used
there is a lack of consistency over de¢nition as well as
over themethodology used to collect the evidence.
Given the objective of satisfying the needs of di¡erent
decision-makers at alternative levels in the health-care
system, but also the normative strength of health maxi-
mization as the primary objective of the system, it is im-
portant to develop an economic analysis with a range of
measures of consequence. The ¢rst step, however,
should be to take a disaggregated cost-consequence ap-
proach, with a ‘balance sheet’ of all relevant costs and a
full range of consequences reported.
Finally, an issue that will require further consideration
is who should be undertaking and funding economic eva-
luation studies. Manufacturers of health-care technolo-
gies, such as pharmaceutical companies, represent an
important source of economic studies (either directly
or through the funding of other groups). Furthermore,
the decisions of reimbursement authorities, such as
those in Canada and Australia, are largely based on sub-
missions from manufacturers. It has been argued that
economic evaluations are more susceptible to bias than
clinical studies (33). Although this point is open to de-bate, reimbursement authorities are likely to have to
fund independent groups either to undertake new eco-
nomic studies or to critically appraise submissions.
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